文献速递神经核医学

在亨廷顿病非人灵长类模型中用11C-CHDI-180R PET对突变亨廷顿蛋白聚集体进行在体脑成像

In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using 11C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease.
PubMed 文献 · J Nucl Med · 2023-08-17

研究在表达85个CAG重复序列的亨廷顿病猕猴模型中验证新型放射性配体11C-CHDI-180R的PET成像效能,结果显示85Q组多个皮层和皮层下脑区结合显著增高,而10Q组与缓冲液组间无差异,组织学证实mHTT聚集体的存在。

要点

  • 11C-CHDI-180R在血浆中代谢稳定,60分钟时母体化合物占比为51.4%±4.0%。
  • 85Q组较对照组在多个皮层和皮层下脑区11C-CHDI-180R结合显著增高(组效应P<0.0001)。
  • 缓冲液组与10Q组间11C-CHDI-180R结合无差异。

核心结论

  • 研究验证了11C-CHDI-180R可作为在亨廷顿病猕猴模型中可视化并定量mHTT聚集物种的放射性配体。
  • 这些发现与既往啮齿类亨廷顿病模型工作相互印证,表明11C-CHDI-180R是评估mHTT聚集体负荷及治疗策略疗效的有前景工具。

研究设计与样本

  • 恒河猴接受MRI引导的纹状体内注射,分别给予表达85个CAG重复序列的AAV2与AAV2.retro混合载体(85Q,n=5)、表达10个CAG重复序列的对照载体(10Q,n=4)或仅载体稀释液(磷酸盐缓冲液,n=5)。
  • 术后30个月进行90分钟动态PET/CT成像,同步连续采血测定输入函数及放射性配体稳定性。
  • 采用两组织室模型及Logan图形分析计算总分布容积以进行区域定量,并行mHTT免疫染色以印证在体所见。

主要发现

  • 11C-CHDI-180R代谢稳定性良好,注射后60分钟血浆中母体化合物占比为51.4%±4.0%。
  • 区域时间-活性曲线显示快速摄取与可逆结合,可由两组织室模型描述。
  • Logan图形分析与两组织室模型相关(r²=0.96,P<0.0001),并用于生成参数化分布容积图。
  • 与对照组相比,给予85Q片段的动物在多个皮层和皮层下脑区11C-CHDI-180R结合显著增高(组效应P<0.0001)。
  • 缓冲液组与10Q组动物间11C-CHDI-180R结合无差异;组织学证实85Q动物存在mHTT聚集体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Huntington disease (HD) is a neurodegenerative disorder caused by an expanded polyglutamine (CAG) trinucleotide expansion in the huntingtin (HTT) gene that encodes the mutant huntingtin protein (mHTT). Visualization and quantification of cerebral mHTT will provide a proxy for target engagement and a means to evaluate therapeutic interventions aimed at lowering mHTT in the brain. Here, we validated the novel radioligand 11C-labeled 6-(5-((5-methoxypyridin-2-yl)methoxy)benzo[d]oxazol-2-yl)-2-methylpyridazin-3(2H)-one (11C-CHDI-180R) using PET imaging to quantify cerebral mHTT aggregates in a macaque model of HD. Methods: Rhesus macaques received MRI-guided intrastriatal delivery of a mixture of AAV2 and AAV2.retro viral vectors expressing an HTT fragment bearing 85 CAG repeats (85Q, n = 5), a control HTT fragment bearing 10 CAG repeats (10Q, n = 4), or vector diluent only (phosphate-buffered saline, n = 5). Thirty months after surgery, 90-min dynamic PET/CT imaging was used to investigate 11C-CHDI-180R brain kinetics, along with serial blood sampling to measure input function and stability of the radioligand. The total volume of distribution was calculated using a 2-tissue-compartment model as well as Logan graphical analysis for regional quantification. Immunostaining for mHTT was performed to corroborate the in vivo findings. Results: 11C-CHDI-180R displayed good metabolic stability (51.4% ± 4.0% parent in plasma at 60 min after injection). Regional time-activity curves displayed rapid uptake and reversible binding, which were described by a 2-tissue-compartment model. Logan graphical analysis was associated with the 2-tissue-compartment model (r 2 = 0.96, P < 0.0001) and used to generate parametric volume of distribution maps. Compared with controls, animals administered the 85Q fragment exhibited significantly increased 11C-CHDI-180R binding in several cortical and subcortical brain regions (group effect, P < 0.0001). No difference in 11C-CHDI-180R binding was observed between buffer and 10Q animals. The presence of mHTT aggregates in the 85Q animals was confirmed histologically. Conclusion: We validated 11C-CHDI-180R as a radioligand to visualize and quantify mHTT aggregated species in a HD macaque model. These findings corroborate our previous work in rodent HD models and show that 11C-CHDI-180R is a promising tool to assess the mHTT aggregate load and the efficacy of therapeutic strategies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bertoglio D, Weiss AR, Liguore W, et al. In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using 11C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease. J Nucl Med. 2023. PMID: 37591545. doi:10.2967/jnumed.123.265569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。